Compare Crispr Therapeutics AG (CRSP) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs T Rowe Price Group Inc — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while T Rowe Price Group Inc trades at $110.99 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 4.6× Crispr Therapeutics AG's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TROW | |
|---|---|---|
Market Cap | $5.23B | $24.26B |
Sector | Health | Financials |
52-Week High | $76.78 | $121.68 |
52-Week Low | $44.34 | $86.19 |
Enterprise Value | $3.65B | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
T. Rowe Price (TROW) trades at $111.17, down 2.29% on the day, with a bearish technical signal driven by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $2.57, supported by record assets under management. Revenue and net income have shown steady growth, with 2025 revenue at $7.31B and net income at $2.09B. The company maintains strong profitability, with a net margin of 29.26% and ROE of 20.1%. Valuation ratios appear reasonable, with a P/E of 11.42 and EV/EBITDA of 6.75. Dividends remain consistent, with a recent quarterly payment of $1.30 declared.
The outlook for TROW is mixed; fundamental strength from earnings growth and solid cash flow supports potential upside, but technical bearishness and analyst caution pose near-term risks. Investment opportunity lies in its undervalued metrics and dividend reliability, while risks include expense pressures and market volatility affecting asset flows. The consensus price target of $112.17 suggests limited upside from current levels, emphasizing a hold stance amid balanced factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
